Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: a population-based study

Ho SO FHKAM, MSc, Joyce Wing-Yan MAK FHKAM, Jacqueline SO MRCP, Grace LUI FHKAM, Frankie LUN FHKAM, Jolly LEE FHKAM, Shirley CHAN MRCP, Carmen HO FHKAM, Jacky Man-Chun CHAN FHKAM, Shing-Pak KONG MRCP, Woon-Leung NG FHKAM, Lai-Shan TAM FHKAM, MD

PII: S0049-0172(20)30214-6
DOI: https://doi.org/10.1016/j.semarthrit.2020.07.012
Reference: YSARH 51703

To appear in: Seminars in Arthritis & Rheumatism

Please cite this article as: Ho SO FHKAM, MSc, Joyce Wing-Yan MAK FHKAM, Jacqueline SO MRCP, Grace LUI FHKAM, Frankie LUN FHKAM, Jolly LEE FHKAM, Shirley CHAN MRCP, Carmen HO FHKAM, Jacky Man-Chun CHAN FHKAM, Shing-Pak KONG MRCP, Woon-Leung NG FHKAM, Lai-Shan TAM FHKAM, MD, Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: a population-based study, Seminars in Arthritis & Rheumatism (2020), doi: https://doi.org/10.1016/j.semarthrit.2020.07.012

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Inc.
Seminars in Arthritis and Rheumatism

Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: a population-based study

Ho SO¹, Joyce Wing-Yan MAK², Jacqueline SO¹, Grace LUI¹, Frankie LUN², Jolly LEE³, Shirley CHAN⁴, Carmen HO⁴, Jacky Man-Chun CHAN⁵, Shing-Pak KONG⁶, Woon-Leung NG⁶, Lai-Shan TAM¹

¹Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
²Institute of Digestive Disease, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
³Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong
⁴Department of Medicine, Queen Mary Hospital, Hong Kong
⁵Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong
⁶Department of Medicine and Geriatrics, United Christian Hospital, Hong Kong

Keywords:
- COVID-19
- SARS-CoV-2
- Incidence
- Outcome

Titles authors: Ho SO (FHKAM, MSc), Joyce Wing-Yan MAK (FHKAM), Jacqueline SO (MRCP), Grace LUI (FHKAM), Frankie LUN (FHKAM), Jolly LEE (FHKAM), Shirley CHAN (MRCP), Carmen HO (FHKAM), Jacky Man-Chun CHAN (FHKAM), Shing-Pak KONG (MRCP), Woon-Leung NG (FHKAM), Lai-Shan TAM (FHKAM, MD)
Corresponding Author: Ho SO, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Room 114042, 9/F, Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital. E-mail: hoso@cuhk.edu.hk

Abstract

Objectives
Patients with rheumatologic diseases might be more susceptible to COVID-19 and carry a poorer prognosis. The aim of this study is to examine the incidence and outcomes of all COVID-19 patients with rheumatologic conditions in Hong Kong.

Methods
This is a population-based retrospective study. All patients tested positive for SARS-CoV-2 by PCR with a previous diagnosis of rheumatologic diseases were reviewed. The incidence of COVID-19 in patients with rheumatologic conditions was calculated and compared to the general population in Hong Kong. Descriptive data of those rheumatologic patients with COVID-19 and the clinical course of the index infection were presented.

Results
Up till 27 May 2020, there were 1067 cases of COVID-19 diagnosed in Hong Kong which had a population of 7.5 million. Out of the 39,835 patients with underlying rheumatologic diseases, we identified 5 PCR confirmed COVID-19 cases. The estimated incidence of COVID-19 was 1.26 cases per 100,000 patients with rheumatologic diseases, compared to 1.42 per 100,000 in the general population. All 5 patients had inflammatory arthropathies. One patient was on hydroxychloroquine and sulphasalazine, and one was on methotrexate. None of the 3534 patients on b/tsDMARDs was infected. Four patients had leucopenia/lymphopenia and stool viral PCR was positive in 3 patients. All patients made uneventful recovery without complications or flare of underlying diseases.

Conclusions
We found no alarming signals of increased frequency or severity of COVID-19 in patients with rheumatologic diseases, although extrapolation of the results to other populations with
different infection control strategies should be made with caution.

**Introduction**

On 12\textsuperscript{th} March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a pandemic \cite{1}. Patients with rheumatologic diseases are at increased risk of infection due to the underlying systemic inflammation and the use of immunosuppressive therapies \cite{2}. They might be more likely to contract the virus. The increased prevalence of comorbidities, such as cardiovascular and pulmonary diseases, in rheumatologic patients have also been reported to be the poor prognostic factors of COVID-19 \cite{3,4}. In contrast, rheumatologic patients might be unexpectedly protected, by virtue of the medications that are using. Much attention has been paid to the controversial anti-SARS-CoV-2 effect of hydroxychloroquine \cite{5}. The other immune-modulators used in our patients may counteract the overwhelming pro-inflammatory cytokines release in the cytokine storm associated with COVID-19 \cite{6}. On the other hand, rheumatologic diseases might be affected by the autoimmunity triggers due to the SARS-CoV-2 \cite{7}.

At the present time, there are mainly self-reported survey or registry data. Large scale population-based studies are lacking. It remains uncertain how rheumatologic diseases or medications will affect the susceptibility and disease course of COVID-19, as well as how SARS-CoV-2 impacts patients with rheumatologic conditions. We aimed to study the incidence, baseline characteristics, disease course and outcomes of COVID-19 patients with rheumatologic diseases in Hong Kong.
Patients and Methods

Study design and Patients
This is a territory-wide multi-centered retrospective observational study. An extensive surveillance scheme was implemented in Hong Kong early in the outbreak. All patients presented to the hospitals with fever, respiratory symptoms or chest x-ray pneumonic changes were tested for SARS-CoV-2 by polymerase chain reaction (PCR) via nasopharyngeal aspiration (NPA). Patients with fever or respiratory symptoms seen in the clinics were also encouraged to undergo the test. Asymptomatic inbound travelers from high risk areas were also tested. All patients tested positive were admitted to the hospitals for further management. The treatments the patients received were at the discretion of the treating physicians.

Data Source
Patient identification was done using the Clinical Data Analysis and Reporting System (CDARS), which was constructed for recordkeeping and research purposes in Hong Kong [8]. It recorded and centralized information on patient demographics, laboratory results, diagnoses, and dates of hospital admissions and discharges. Data validation in CDARS demonstrated a high coding accuracy and the system has been extensively used in large-scale epidemiological studies [9-12]. Patients with a positive SARS-CoV-2 PCR test and any rheumatologic diagnosis were identified from the CDARS. The investigators of the study would then review the records of each patient to verify the diagnoses and collect the clinical data. The total numbers of living patients with International Classification of Diseases Ninth Revision (ICD-9) diagnostic codes for rheumatoid arthritis (RA), systemic lupus erythematosus, ankylosing spondylitis (AS), psoriatic arthropathy (PsA), scleroderma, dermatomyositis, polymyositis, systemic vasculitis, adult onset Still’s disease and mixed connective tissue disease who have been registered in the CDARS were retrieved. The data search and analysis was up to 26th May, 2020.
Statistical Analysis

Due to the small number of cases, only descriptive data were presented. The incidence of rheumatologic patients with COVID-19 in the Hong Kong population was calculated. The incidence of the COVID-19 infection in rheumatologic patients was deduced using a crude estimation of the number of patients with rheumatologic conditions in Hong Kong. It was numerically compared with the overall Hong Kong incidence of COVID-19 infection.

Ethical approval

The study was approved by the Institutional Review Board of the University of Hong Kong and the Hospital Authority Hong Kong West Cluster (UW20-389), Joint Chinese University of Hong Kong – New Territories East Cluster Clinical Research Ethics Committee (NTEC-2020-0248) and Kowloon Central Cluster REC / Kowloon East Cluster REC (20-0121/ER-1). This study was conducted according to the principles of the Declaration of Helsinki.

Results

Since 23rd January when the first case was confirmed to the time of writing on 27th May, there were 1067 cases of COVID-19 diagnosed in Hong Kong. There was a downward trend of new cases reported as shown in figure 1. So far there were 4 deaths and one patient who was still in critical condition. We identified 5 COVID-19 patients with underlying rheumatologic diseases during this period, making the incidence rate of rheumatologic patients with COVID-19 in the Hong Kong, which has a population of 7.5 million as of end of 2019, 6.7 cases per 100,000 inhabitants. There were 39,835 patients with rheumatologic diseases in Hong Kong from CDARS search. The estimated incidence of COVID-19 was 1.26 cases per 100,000 patients with
rheumatologic diseases, compared to 1.42 per 100,000 in the general Hong Kong population. None of the 3534 patients (at the time of writing) in the Hong Kong Biologics Registry who were on biologic or targeted synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs) was infected. Of note, 4 out of the 5 confirmed cases were believed to be imported.

The baseline characteristics and clinical features of the 5 patients were presented in table 1. All of the patients had arthritides (3 AS, 1 RA and 1 PsA). No patient with other connective tissue diseases was diagnosed to have COVID-19. Of the 5 infected patients, one was on hydroxychloroquine/sulphasalazine combination and another patient was on methotrexate. Only methotrexate was stopped due to the infection after hospitalization. All of them presented with respiratory symptoms, and two had diarrhea and vomiting. Besides NPA, 2 patients with diarrhea and 1 without were tested positive for stool viral PCR. Four out of 5 patients had leucopenia and lymphopenia. They mostly had mild COVID-19 disease without developing any significant complication. Only one patient required supplementary oxygen therapy temporarily. Remdesivir was given in 2 patients including the one requiring oxygen therapy. Lopinavir/ritonavir in combination with interferon beta were given in another patient. Their symptoms resolved in 7 to 14 days and viral clearance was documented in 19 to 31 days. There was no obvious flare of the underlying rheumatologic diseases before discharge from the hospital which was no later than the date of viral clearance.

**Discussions**

In this territory-wide population-based study, we found an apparently low incidence of laboratory proven COVID-19 in patients with rheumatologic disease in Hong Kong, which was similar to that of the general public. Monti and colleagues provided an early account of patients with arthritis in Lombardy, Italy, one of the most heavily hit regions [13]. Out of the 320 surveyed patients, 4 (1.25%) were diagnosed of COVID-19 infection. In a study conducted in Milan, out of 530 patients on b/tsDMARDs, 3 (0.57%) were diagnosed to have COVID-19 by PCR
In another Italian cohort from a different region, only 2 (0.21%) of the 916 patients with rheumatologic diseases were virologically diagnosed to have COVID-19 and the incidence was not significantly different from the general population [15]. A similar finding of comparable COVID-19 incidence rate between rheumatologic patients and the general population (0.48% and 0.58% respectively) was again reported in a Spanish study [16]. However, all of the above studies were conducted in the form of patient self-reported survey which might affect the validity of the results.

Whether rheumatologic disease is a poor prognostic factor for COVID-19 is debatable. In our study, the disease courses of the 5 patients with COVID-19 were largely uneventful. A similarly reassuring message was conveyed from the above mentioned Italian cohorts. On the other hand, early data from the COVID-19 Global Rheumatology Alliance, the international initiative to collect data of rheumatologic patients with COVID-19, revealed an overall death rate of 5% in 110 cases [17]. In a French report of 17 systemic lupus erythematosus patients with COVID-19, 5 patients required invasive mechanical ventilation and 2 patients died [18]. In the latest report from the Global Rheumatology Alliance, corticosteroids use was found to be the poor prognostic factor, and patients on anti-TNFs had a decreased odds of hospitalization [19]. However, as these are survey or registry data, they are subject to selection or reporting bias.

Leucopenia and gastro-intestinal (GI) symptoms were common in our patients and might be a unique finding. A systemic review showed a high frequency of lymphopenia but not leucopenia in patients with COVID-19 [20]. Lymphocytes, the major antiviral cells, were found to be prone to decrease continually in patients with severe COVID-19 [21]. At the same time, as the illness progressed, neutrophilia emerged and was an indicator of poor prognosis [22]. This might explain the relatively low total leucocyte counts in our patients with benign disease courses. On the other hand, another review suggested that 12% of patients with COVID-19 would manifest GI symptoms, although viral shedding was observed in 40.5% of patients [23]. The diagnostic, prognostic and infection control implications of these findings need to be further studied.
Anti-endemic measures, including border restrictions, quarantine, and social distancing were implemented early to curb the spread of the infection in Hong Kong [24]. All these, but without complete society lock-down, together with a 96.6% compliance of mask usage of the general public were believed to the reasons for the low overall incidence of COVID-19 in Hong Kong [25]. The potentially even more stringent behavioral measures adopted by our rheumatologic patients due to the awareness of an increased risk, may lead to underestimation of the true incidence. The different testing strategies applied could have equally affected the rate of COVID-19 diagnosis. The number of COVID-19 PCR tests performed in Hong Kong was 27,057 per million population, which was comparable to most of the developed countries [26,27]. It is also possible that the COVID-19 infections presented to us are only the tip of the iceberg, as the many of cases are asymptomatic or minimally symptomatic. We extended the testing to asymptomatic inbound travelers. No asymptomatic COVID-19 patient with rheumatologic diseases was found. Unfortunately, wide-spread serological testing was not done which might provide a better picture of the epidemiology of the disease. Another major limitation of our study is the small sample size of the COVID-19 patients which hampered the inference of our results.

To conclude, our findings could provide further reassurance about the incidence and possibly outcome of COVID-19 in patients with rheumatologic diseases. Nevertheless, these should be interpreted in the context of all the mitigation measures implemented in Hong Kong, and may not be applicable to other parts of the world adopting different strategies. The results also support avoidance of interrupting immunosuppressive therapies, at least before COVID-19 is diagnosed. The implications of the apparent high frequency of leucopenia and positive stool viral PCR require further investigations.

**Acknowledgements** None

**Patient consent for publication** Not required.

**Data availability statement** Data can be shared upon request.
References

1. World Health Organization. Coronavirus disease (COVID-19) outbreak. [Cited 2020 May 26]. Available from: http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/.

2. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287-93.

3. Kuo CF, Chou IJ, Rees F. Temporal relationships between systemic lupus erythematosus and comorbidities. Rheumatology. 2019;58:840-8.

4. Chen D, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020. doi: https://doi.org/10.1136/bmj.m1091.

5. Taccone FS, Gorham J, Vincent J-L. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med 2020. doi:10.1016/S2213-2600(20)30172-7.

6. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China. Clin Immunol. 2020;214: 108393.

7. Shamriz O, Shoenfeld Y. Infections: A double-edge sword in autoimmunity. Curr Opin Rheumatol. 2018;30:365-72.

8. Hospital Authority. Introduction: caring for our community's health. [cited 2020 May 26]. Available from: https://www.ha.org.hk/visitor/ha_visitor_index.asp?Content_ID=10008&Lang=ENG&Dimension=100&Parent_ID=10004/.
9. Sing CW, Woo YC, Lee ACH, Lam JKY, Chu JKP, Wong ICK, et al. Validity of major osteoporotic fracture diagnosis codes in the Clinical Data Analysis and Reporting System in Hong Kong. Pharmacoepidemiol Drug Saf. 2017;26:973-6.
10. Chiu SS, Lau YL, Chan KH, Peiris JSM. Influenza-related hospitalizations among children in Hong Kong. N Engl J Med. 2002;347:2097-103.
11. Lau WC, Chan EW, Cheung CL, Sing CW, Man KKC, Lip GYH, et al. Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation. JAMA. 2017;317:1151-1158.
12. Yip TC, Chan LH, Wong WV, Tse Y, Lam KL, Wong GL. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol. 2017;67:902-8.
13. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79:667–8.
14. Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. 2020. doi:10.1136/annrheumdis-2020-217615
15. Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, et al. SARS-CoV-2 Infection in Patients With Autoimmune Rheumatic Diseases in Northeast Italy: A Cross-Sectional Study on 916 Patients. J Autoimmun. 2020 Jun 8. doi.org/10.1016/j.jaut.2020.102502
16. Michelena X, Borrell H, Lopez-Corbeto M, Lopez-Lasanta M, Moreno E, Pascual-Pastor M, et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020;50:564-70.
17. Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2020 Apr 16. doi: 10.1016/S2665-9913(20)30095-3.
18. Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020. doi: 10.1136/annrheumdis-2020-217566.

19. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila M, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020;79:859–66.

20. Liu X, Zhang R, Ge G. Hematological findings in coronavirus disease 2019: indications of progression of disease. Ann Hematol. 2020;3:1–8.

21. Wang DW, Hu B, Hu C, Zhu FF, Liu X, Zhang J, et al. (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069.

22. Fan BE, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol 2020. https://doi.org/10.1002/ajh.25774.

23. Parasa S, Desai M, Chandrasekar VT, Patel HK, Kennedy KF, Roesch T, et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: a systematic review and meta-analysis. JAMA Network Open. 2020;3(6):e2011335.

24. Cowling BJ, Ali ST, Ng TWY, Tsang TK, Li JCM, Fong MW, et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet Public Health 2020. doi.org/10.1016/ S2468-2667(20)30090-6.

25. Cheng VCC, Wong SC, Chuang VWM, So SY, Chen JH, Sridhar S, et al. The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2. J Infect 2020. doi: 10.1016/j.jinf.2020.04.024.

26. Centre for Health Protection, The Government of the Hong Kong Special Administrative Region. Statistics on Testing for COVID-19 in Hong Kong. [Cited 2020 May 26] Available from: https://www.chp.gov.hk/files/pdf/statistics_on_covid_19_testing.pdf.
27. Statista. Rate of COVID-19 testing in most impacted countries worldwide as of May 29, 2020. [Cited 2020 May 26]. Available from: https://www.statista.com/statistics/1104645/covid19-testing-rate-select-countries-worldwide/.

Contributors All authors have substantially contributed to all aspects of this study. HS, JWM, GL and LT: study design, data analysis and interpretation, drafting the manuscript. JS, FL, JL, SC, CH, JMC, SK and WN: data acquisition. All authors critically revised and approved the final version of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Acknowledgements None

Data availability statement Data can be shared upon request.

Figure Legend

Figure 1 1067 confirmed cases of COVID-19 in Hong Kong (as of 27th May, 2020)
Figure 1 1067 confirmed cases of COVID-19 in Hong Kong (as of 27th May, 2020)
**Table 1.** The baseline characteristics and clinical features of the 5 COVID-19 patients with rheumatologic diseases

|                          | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 |
|--------------------------|--------|--------|--------|--------|--------|
| **Baseline characteristics** |        |        |        |        |        |
| Age                      | 59     | 23     | 66     | 61     | 25     |
| Gender                   | Male   | Female | Male   | Female | Male   |
| Race                     | Chinese| Chinese| Chinese| Chinese| White  |
| Smoking                  | Ex-smoker | Smoker | No     | No     | Unknown|
| Comorbidities            | None   | None   | DM, HT | None   | None   |
| Rheumatologic diagnosis  | ankylosing spondylitis | ankylosing spondylitis | Psoriatic arthritis | Rheumatoid arthritis | ankylosing spondylitis |
| Disease activity         | Moderate | Low   | Low    | Low    | Remission |
| Treatment received       | None   | None   | MTX (stopped) | HCQ (continued), SSZ (Continued) | None |
| (stopped/continued after COVID-19) |        |        |        |        |        |
| Other medications        | None   | None   | NSAID, PD5i | COX2i | None   |
| **Covid-19 features**    |        |        |        |        |        |
| Diagnosis date           | 13/3/2020 | 18/3/2020 | 23/3/2020 | 5/4/2020 | 20/4/2020 |
| Diagnosis location       | Government outpatient | Private outpatient | Inpatient | Quarantine Services | Government outpatient |
| Diagnosis method (sites) | PCR (NPA/NPS, deep throat sputum, stool) | PCR (NPA/NPS, deep throat sputum, stool) | PCR (NPA/NPS, deep throat sputum, stool) | PCR (NPA/NPS, deep throat sputum) | PCR (NPA/NPS, deep throat sputum) |
| Epidemiological link      | Confirmed cases in same building | From United Kingdom | From Macau | From Nigeria | From United Kingdom |
| Symptoms                 | Fever, sore throat, cough, diarrhea, vomiting | Sore throat, cough, myalgia | Fever, cough, SOB, diarrhea/vomiting | Rhinorrhea, anosmia | Anosmia |
| Treatment for COVID-19   | Remdesivir | None except supportive | Remdesivir | Kaletra, interferon beta | None except supportive |
| Maximal level of care    | No need oxygen | No need oxygen | Supplemental oxygen (3L nasal cannula) | No need oxygen | No need oxygen |
| Complications            | None   | None   | None   | None   | None   |
| Co-infection             | No     | No     | No     | No     | No     |
| Anaemia < 9.2            | No     | No     | No     | No     | No     |
| Leukopenia < 5           | Yes    | Yes    | Yes    | Yes    | No     |
| Lymphopenia <1.5         | Yes    | Yes    | Yes    | Yes    | No     |
| Thrombocytopenia         | No     | No     | No     | No     | No     |
| <110 | D-dimer > ULN | N/A | N/A | Yes | Yes | No |
|------|--------------|-----|-----|-----|-----|----|
| AST/ALT > ULN | No | No | No | Yes | No |
| Deceased | No | No | No | No | No |
| Duration till symptoms resolution | 14 days | 7 days | 10 days | 7 days | 12 days |
| Duration from symptom onset to viral clearance (<ve PCR x 2) | 31 days | 26 days | 19 days | 27 days | 28 days |

DM: diabetes mellitus, HT: hypertension, MTX: methotrexate, HCQ: hydroxychloroquine, SSZ (sulphasalazine), NSAID: non-steroidal anti-inflammatory drugs, PD5i: phosphodiesterase-5 inhibitor, COX2i: cyclooxygenase-2 inhibitor, PCR: polymerase chain reaction, NPA: nasopharyngeal aspirate, NPS: nasopharyngeal swab, SOB: shortness of breath, ULN: upper limit of normal